2016 Q1 Form 10-Q Financial Statement
#000143774916031685 Filed on May 12, 2016
Income Statement
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| Revenue | $1.719M | $538.0K |
| YoY Change | 219.52% | 85.52% |
| Cost Of Revenue | $611.0K | $148.0K |
| YoY Change | 312.84% | 13.85% |
| Gross Profit | $1.108M | $390.0K |
| YoY Change | 184.1% | 143.75% |
| Gross Profit Margin | 64.46% | 72.49% |
| Selling, General & Admin | $4.826M | $3.468M |
| YoY Change | 39.16% | 102.81% |
| % of Gross Profit | 435.56% | 889.23% |
| Research & Development | $933.0K | $1.583M |
| YoY Change | -41.06% | -37.92% |
| % of Gross Profit | 84.21% | 405.9% |
| Depreciation & Amortization | $40.00K | $41.00K |
| YoY Change | -2.44% | -41.43% |
| % of Gross Profit | 3.61% | 10.51% |
| Operating Expenses | $5.759M | $5.051M |
| YoY Change | 14.02% | 18.57% |
| Operating Profit | -$4.651M | -$4.661M |
| YoY Change | -0.21% | 13.68% |
| Interest Expense | -$390.0K | $30.00K |
| YoY Change | -1400.0% | -94.23% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$41.00K | -$11.00K |
| YoY Change | 272.73% | -210.0% |
| Pretax Income | -$5.077M | -$4.638M |
| YoY Change | 9.47% | 29.92% |
| Income Tax | $2.000K | |
| % Of Pretax Income | ||
| Net Earnings | -$5.077M | -$4.640M |
| YoY Change | 9.42% | 29.97% |
| Net Earnings / Revenue | -295.35% | -862.45% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$1.242M | -$2.138M |
| COMMON SHARES | ||
| Basic Shares Outstanding | 4.086M | 2.175M |
| Diluted Shares Outstanding | 4.086M | 2.175M |
Balance Sheet
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $1.430M | $5.600M |
| YoY Change | -74.46% | -63.09% |
| Cash & Equivalents | $1.430M | $5.598M |
| Short-Term Investments | ||
| Other Short-Term Assets | $430.0K | $1.220M |
| YoY Change | -64.75% | 54.43% |
| Inventory | $1.201M | $490.0K |
| Prepaid Expenses | $433.0K | |
| Receivables | $1.500M | $280.0K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $4.561M | $7.600M |
| YoY Change | -39.99% | -53.6% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $370.0K | $410.0K |
| YoY Change | -9.76% | -37.88% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $150.0K | |
| YoY Change | 7.14% | |
| Total Long-Term Assets | $370.0K | $560.0K |
| YoY Change | -33.93% | -30.86% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $4.561M | $7.600M |
| Total Long-Term Assets | $370.0K | $560.0K |
| Total Assets | $4.931M | $8.160M |
| YoY Change | -39.57% | -52.53% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.820M | $2.180M |
| YoY Change | -16.51% | 344.9% |
| Accrued Expenses | $2.019M | $1.100M |
| YoY Change | 83.55% | -31.25% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $4.028M | $3.700M |
| YoY Change | 8.86% | 62.28% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $3.060M | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $5.140M | $2.310M |
| YoY Change | 122.51% | -24.76% |
| Total Long-Term Liabilities | $8.200M | $2.310M |
| YoY Change | 254.98% | -24.76% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $4.028M | $3.700M |
| Total Long-Term Liabilities | $8.200M | $2.310M |
| Total Liabilities | $12.23M | $6.010M |
| YoY Change | 103.49% | 12.34% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$95.60M | |
| YoY Change | ||
| Common Stock | $51.00K | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$7.300M | $2.150M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $4.931M | $8.160M |
| YoY Change | -39.57% | -52.53% |
Cashflow Statement
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$5.077M | -$4.640M |
| YoY Change | 9.42% | 29.97% |
| Depreciation, Depletion And Amortization | $40.00K | $41.00K |
| YoY Change | -2.44% | -41.43% |
| Cash From Operating Activities | -$4.932M | -$4.507M |
| YoY Change | 9.43% | 1.97% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $16.00K | $14.00K |
| YoY Change | 14.29% | -240.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $40.00K |
| YoY Change | -100.0% | -101.73% |
| Cash From Investing Activities | -$16.00K | $23.00K |
| YoY Change | -169.57% | -100.99% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $2.628M | $4.700M |
| YoY Change | -44.09% | -29.85% |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 3.993M | 4.653M |
| YoY Change | -14.18% | -29.07% |
| NET CHANGE | ||
| Cash From Operating Activities | -4.932M | -4.507M |
| Cash From Investing Activities | -16.00K | 23.00K |
| Cash From Financing Activities | 3.993M | 4.653M |
| Net Change In Cash | -955.0K | 169.0K |
| YoY Change | -665.09% | -193.89% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$4.932M | -$4.507M |
| Capital Expenditures | $16.00K | $14.00K |
| Free Cash Flow | -$4.948M | -$4.521M |
| YoY Change | 9.44% | 2.52% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2016Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2016Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2016 | |
| CY2016Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2016Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2016-03-31 | |
| CY2016Q1 | nby |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
451000 | |
| CY2015Q4 | nby |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
394000 | |
| CY2016Q1 | nby |
Allowance For Obsolete Inventory Decrease From Disposal Of Obsolete Inventory
AllowanceForObsoleteInventoryDecreaseFromDisposalOfObsoleteInventory
|
45000 | |
| CY2012Q4 | nby |
Excess Fair Value Over Proceeds Received From Purchase
ExcessFairValueOverProceedsReceivedFromPurchase
|
1000000 | |
| CY2012Q1 | nby |
Minimum Common Stock Closing Bid Price Per Share
MinimumCommonStockClosingBidPricePerShare
|
66.50 | |
| CY2016Q1 | nby |
Note Receivable Impairment
NoteReceivableImpairment
|
91000 | |
| CY2015Q1 | nby |
Note Receivable Impairment
NoteReceivableImpairment
|
||
| CY2007Q3 | nby |
Number Of Subsidiaries
NumberOfSubsidiaries
|
2 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber
|
300000 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice
|
34.63 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm
|
P5Y146D | |
| CY2015Q4 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
|
388000 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding
|
461000 | |
| CY2015Q4 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
|
32.03 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice
|
24.93 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
31000 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber
|
456000 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
25.04 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
|
P11Y | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod
|
300000 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue
|
34.63 | |
| CY2016Q1 | nby |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm
|
P5Y146D | |
| CY2016Q1 | nby |
Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
|
133000 | |
| CY2015Q1 | nby |
Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
|
||
| CY2016Q1 | nby |
Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
|
21000 | |
| CY2015Q1 | nby |
Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees
StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
|
||
| CY2016Q1 | us-gaap |
Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
|
1497000 | |
| CY2015Q4 | us-gaap |
Accounts Notes And Loans Receivable Net Current
AccountsNotesAndLoansReceivableNetCurrent
|
536000 | |
| CY2016Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1820000 | |
| CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2483000 | |
| CY2016Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2019000 | |
| CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1980000 | |
| CY2016Q1 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
64000 | |
| CY2015Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
150000 | |
| CY2016Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1742000 | |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1702000 | |
| CY2016Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
88248000 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
85387000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
247000 | |
| CY2015Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
285000 | |
| CY2016Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
71000 | |
| CY2015Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
40000 | |
| CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
240000 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
5075 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1758000 | |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1191000 | |
| CY2016Q1 | us-gaap |
Assets
Assets
|
4931000 | |
| CY2015Q4 | us-gaap |
Assets
Assets
|
5077000 | |
| CY2016Q1 | us-gaap |
Assets Current
AssetsCurrent
|
4561000 | |
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
4527000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1430000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2385000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5429000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5598000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-955000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
169000 | |
| CY2011Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
33.25 | |
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.19 | |
| CY2016Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
4.58 | |
| CY2016Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1237976 | |
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1458000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
3486 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
5075 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
3486 | |
| CY2016Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
51000 | |
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
35000 | |
| CY2016Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
385000 | |
| CY2015Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-34000 | |
| CY2016Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk and Major Partners</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains deposits of cash, cash equivalents and short-term investments with three highly-rated, major financial institutions in the United States.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deposits in these banks may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held. Additionally, the Company has established guidelines regarding diversification and investment maturities, which are designed to maintain safety and liquidity.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the three months ended March 31, 2016, revenues were derived primarily from sales of Avenova directly to doctors through the Company’s webstore and to three distribution partners. During the three months ended March 31, 2015, revenues were derived from one collaboration partner, service revenues and sales of NeutroPhase.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2016, 33%, 24% and 10% of accounts receivable were derived from the Company’s three primary distribution partners. As of December 31, 2015, 41% and 18% of accounts receivable were derived from the Company’s two primary distribution partners.</div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2013Q1 | us-gaap |
Contracts Revenue
ContractsRevenue
|
313000 | |
| CY2016Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
611000 | |
| CY2015Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
148000 | |
| CY2016Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
189000 | |
| CY2015Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
189000 | |
| CY2016Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
189000 | |
| CY2015Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
170000 | |
| CY2016Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
3115000 | |
| CY2015Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
2248000 | |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
40000 | |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
41000 | |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
40000 | |
| CY2015Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
41000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.24 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.13 | |
| CY2016Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
514000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
614000 | |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
882000 | |
| CY2012Q1 | us-gaap |
Fees And Commissions Other
FeesAndCommissionsOther
|
313000 | |
| CY2016Q1 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
||
| CY2015Q1 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
1000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1655000 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1554000 | |
| CY2016Q1 | us-gaap |
Gross Profit
GrossProfit
|
1108000 | |
| CY2015Q1 | us-gaap |
Gross Profit
GrossProfit
|
390000 | |
| CY2016Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-5077000 | |
| CY2015Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-4638000 | |
| CY2016Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2015Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2000 | |
| CY2016Q1 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
824000 | |
| CY2015Q4 | us-gaap |
Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
|
660000 | |
| CY2016Q1 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
||
| CY2015Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
45000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-580000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
357000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
992000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
117000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
886000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-6000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-144000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-29000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
107000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
491000 | |
| CY2016Q1 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
263000 | |
| CY2015Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
482000 | |
| CY2016Q1 | us-gaap |
Inventory Net
InventoryNet
|
1201000 | |
| CY2015Q4 | us-gaap |
Inventory Net
InventoryNet
|
1345000 | |
| CY2016Q1 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
114000 | |
| CY2015Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
248000 | |
| CY2016Q1 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
253000 | |
| CY2015Q1 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
256000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
232000 | |
| CY2016Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
||
| CY2015Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
155000 | |
| CY2016Q1 | us-gaap |
Other Income
OtherIncome
|
51000 | |
| CY2015Q1 | us-gaap |
Other Income
OtherIncome
|
6000 | |
| CY2016Q1 | us-gaap |
Liabilities
Liabilities
|
12230000 | |
| CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
10175000 | |
| CY2016Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
4931000 | |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
5077000 | |
| CY2016Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4028000 | |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4633000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3993000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4653000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-16000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
23000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4932000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4507000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5077000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4640000 | |
| CY2011Q3 | us-gaap |
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
|
139520 | |
| CY2016Q1 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
3063000 | |
| CY2015Q4 | us-gaap |
Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
|
1655000 | |
| CY2015 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
4 | |
| CY2016Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
5732000 | |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
5051000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4624000 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4661000 | |
| CY2016Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
399000 | |
| CY2016Q1 | us-gaap |
Other Liabilities
OtherLiabilities
|
1835000 | |
| CY2016Q1 | us-gaap |
Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
|
-385000 | |
| CY2015Q1 | us-gaap |
Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
|
34000 | |
| CY2016Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-68000 | |
| CY2015Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-11000 | |
| CY2016Q1 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
64000 | |
| CY2015Q1 | us-gaap |
Other Sales Revenue Net
OtherSalesRevenueNet
|
46000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
16000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
14000 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
433000 | |
| CY2015Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
261000 | |
| CY2016Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders’ equity. </div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2628000 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
||
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
1365000 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
||
| CY2016Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
||
| CY2015Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
4653000 | |
| CY2016Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
||
| CY2015Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
37000 | |
| CY2016Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-5077000 | |
| CY2015Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-4640000 | |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2112000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2097000 | |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
370000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
395000 | |
| CY2016Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
31000 | |
| CY2015Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
70000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
933000 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1583000 | |
| CY2016Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-95598000 | |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-90520000 | |
| CY2016Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
1655000 | |
| CY2015Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
492000 | |
| CY2016Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1719000 | |
| CY2015Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
538000 | |
| CY2016Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
3144000 | |
| CY2015Q1 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1914000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
74000 | |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
265000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P2Y7D | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
73000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
72000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
4000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
36000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
108000 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
19000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
31000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
31.80 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
2.20 | |
| CY2016Q1 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
|
-19000 | |
| CY2015Q1 | us-gaap |
Share Based Goods And Nonemployee Services Transaction Stockholders Equity
ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity
|
-20000 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y73D | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P11Y | |
| CY2016Q1 | us-gaap |
Stock Issued1
StockIssued1
|
1000 | |
| CY2015Q1 | us-gaap |
Stock Issued1
StockIssued1
|
||
| CY2016Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1518567 | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2800000 | |
| CY2016Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-7299000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
-5098000 | |
| CY2016Q1 | us-gaap |
Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
|
591000 | |
| CY2015Q4 | us-gaap |
Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
|
590000 | |
| CY2016Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2015Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1450000 | |
| CY2016Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1834991 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
4086000 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
2175000 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
4086 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
2175 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
4086000 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
2175000 |
